Your browser doesn't support javascript.
loading
Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer.
Müller, Volkmar; Wöckel, Achim; Lux, Michael P; Janni, Wolfgang; Hartkopf, Andreas D; Nabieva, Naiba; Taran, Florin-Andrei; Hadji, Peyman; Tesch, Hans; Ettl, Johannes; Lüftner, Diana; Welslau, Manfred; Belleville, Erik; Brucker, Sara Y; Schütz, Florian; Fasching, Peter A; Fehm, Tanja N; Kolberg, Hans-Christian; Schneeweiss, Andreas; Overkamp, Friedrich.
  • Müller V; Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
  • Wöckel A; Department of Gynecology and Obstetrics, University Hospital Würzburg, Germany.
  • Lux MP; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Janni W; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
  • Hartkopf AD; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Nabieva N; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Taran FA; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Hadji P; Department of Bone Oncology, Nordwest Hospital, Frankfurt, Germany.
  • Tesch H; Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany.
  • Ettl J; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Lüftner D; Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany.
  • Welslau M; Onkologie Aschaffenburg, Hämatolo-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg, Aschaffenburg, Germany.
  • Belleville E; ClinSol GmbH & Co. KG, Würzburg, Germany.
  • Brucker SY; Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  • Schütz F; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
  • Fasching PA; Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Fehm TN; Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
  • Kolberg HC; Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
  • Schneeweiss A; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
  • Overkamp F; National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany.
Geburtshilfe Frauenheilkd ; 78(11): 1119-1128, 2018 Nov.
Article en En | MEDLINE | ID: mdl-30498279
ABSTRACT
New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class of substances (palbociclib, ribociclib and abemaciclib). Further pathways under investigation are PI3K and AKT signalling pathways along with diverse approaches to their inhibition. Initial study results were also presented recently on both mechanisms of action. Insights into the PARP inhibitors, moreover, are increasing; studies in this respect are also examining in which population they can be used most effectively. This review offers a summary of the recent studies and an outline of the latest developments.
Palabras clave